Our response to the Scottish Medicines Consortium's announcement to approve the breast cancer drug fulvestrant on the NHS.
Improving access to life-extending medicines forms part of our 2050 Challenge campaign, which asks MSPs to help stop deaths from breast cancer by 2050.
The Scottish Medicines Consortium (SMC) approves drugs for use on the NHS and have recently announced their decision to accept the breast cancer drug fulvestrant (Faslodex) for use on the NHS in Scotland.
Commenting on the SMC’s announcement, Breast Cancer Now’s Director for Scotland, Mary Allison, said:
“We welcome this decision to unlock more options for women with incurable secondary breast cancer and the doctors who care for them. However, that doesn’t mean that the drugs approval system is working at its best.
“A number of very promising life-extending drugs have been rejected by this same process. We believe that the way we approve drugs for use on the NHS in Scotland can work better to get a fairer deal for patients and the health service.
“Through our 2050 Challenge campaign, we have brought forward clear proposals that we believe could improve access to life-extending drugs in Scotland. We welcome the Scottish Government’s commitment to review the system and will be feeding our proposals into the review.”